HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial.

Abstract
Seventy patients with stage III or IV endometriosis were randomly assigned to 2 groups after conservative surgery. Group O (n = 35) received 3 cycles of a 28-day gonadotropin-releasing hormone agonist (GnRH-a) treatment (goserelin, 3.6 mg) starting 3-5 days postoperatively. Group M (n = 35) received the same treatment starting on days 1-5 of menstruation. Groups were further subdivided according to add-back treatment. Pre- and posttreated levels of estradiol (E2 ), follicle stimulating hormone (FSH), and luteinizing hormone (LH) and visual analog scale (VAS), Kupperman menopausal index (KMI), and bone mineral density (BMD) scores were recorded. The incidence of uterine bleeding was assessed. In both groups, serum levels of E2 , FSH, and LH and VAS scores decreased significantly after treatment. Spotting was the most frequent bleeding pattern. During cycle 1, the bleeding time in group M was much longer that than that in group O (P =.001), and the bleeding rate in group M was significantly higher than that in group O (P =.024, RR = 1.185). In patients with stage III or IV endometriosis, the efficacy of GnRH-a initiated 3-5 days postoperatively was equivalent to that of GnRH-a initiated on days 1-5 of menstruation. Female patients who initiated GnRH-a treatment 3-5 days postoperatively experienced less uterine bleeding during the first cycle of treatment.
AuthorsLili Gong, Shaofen Zhang, Yi Han, Qiqi Long, Shien Zou, Yuankui Cao
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 55 Issue 8 Pg. 848-53 (Aug 2015) ISSN: 1552-4604 [Electronic] England
PMID25694383 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2015, The American College of Clinical Pharmacology.
Chemical References
  • Goserelin
  • Gonadotropin-Releasing Hormone
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
Topics
  • Adult
  • Drug Administration Schedule
  • Endometriosis (blood, drug therapy)
  • Estradiol (blood)
  • Female
  • Follicle Stimulating Hormone (blood)
  • Gonadotropin-Releasing Hormone (agonists)
  • Goserelin (administration & dosage, therapeutic use)
  • Humans
  • Luteinizing Hormone (blood)
  • Menstruation
  • Middle Aged
  • Postoperative Period
  • Uterine Hemorrhage (chemically induced)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: